focus -WSS

focus

author：fashion 2025-09-30 14:58:25 - browse：3578

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Diversifying clinical trials isn't enough to close racial gaps: study

hotspot

WSS

Why Sanofi got shellacked over its spinoff

Diversifying clinical trials isn't enough to close racial gaps: study

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Why Sanofi got shellacked over its spinoff

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Eli Lilly to acquire Versanis in heated race for weight loss drugs

focus

focus

leisure time

At least 13 dead in Texas as scorching temps continue

The new HIV moral panic

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

At least 13 dead in Texas as scorching temps continue

The FDA weighs the risks of candy

The cancer drug shortage isn’t new — and neither are the solutions

Emergency medicine has repudiated 'excited delirium.' Now what?

Bright Health sells Medicare Advantage business to Molina

Mike Pence clashes with Tucker Carlson in Iowa

focus

Care demand spikes challenge UnitedHealth’s provider arm

Involuntary treatment for addiction doesn't work

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Europe sees delivery challenges ahead on Alzheimer's therapies

Senate panel to vote on hospitals, PBMs, prisoner care

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

leisure time

hotspot

focus

hotspot